2018 News Releases
News Releases |
Axsome Therapeutics Announces AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
January 9, 2018
COAST-1 is a Phase 3 trial of AXS-02 in knee osteoarthritis associated with bone marrow lesions CREATE-1 is a Phase 3 trial of AXS-02 in complex regional pain syndrome Significant reduction in bone resorption confirms potent pharmacologic activity Company to host conference call today at 8:00 AM Eastern NEW YORK, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central n...
Financial Tear Sheet